Westfield Capital Management Co. LP Sells 7,970 Shares of Masimo Co. (NASDAQ:MASI)
Westfield Capital Management Co. LP lowered its position in shares of Masimo Co. (NASDAQ:MASI) by 4.1% in the second quarter, HoldingsChannel reports. The firm owned 187,977 shares of the medical equipment provider’s stock after selling 7,970 shares during the period. Westfield Capital Management Co. LP’s holdings in Masimo were worth $27,975,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Envestnet Asset Management Inc. boosted its position in Masimo by 15.4% in the first quarter. Envestnet Asset Management Inc. now owns 32,899 shares of the medical equipment provider’s stock valued at $4,549,000 after buying an additional 4,394 shares in the last quarter. Empowered Funds LLC bought a new stake in Masimo during the first quarter worth about $1,572,000. Machina Capital S.A.S. acquired a new stake in shares of Masimo during the second quarter worth approximately $209,000. FMR LLC increased its holdings in shares of Masimo by 7.4% during the first quarter. FMR LLC now owns 4,178,808 shares of the medical equipment provider’s stock worth $577,845,000 after buying an additional 289,246 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Masimo by 10.6% in the second quarter. Bank of New York Mellon Corp now owns 694,217 shares of the medical equipment provider’s stock valued at $103,312,000 after acquiring an additional 66,444 shares during the last quarter. Institutional investors and hedge funds own 84.07% of the company’s stock.
MASI has been the topic of a number of research analyst reports. BidaskClub lowered Masimo from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 6th. BTIG Research restated a “hold” rating on shares of Masimo in a research report on Thursday, August 1st. Piper Jaffray Companies lifted their price target on shares of Masimo from $148.00 to $160.00 in a research report on Friday, May 17th. UBS Group boosted their price target on shares of Masimo from $172.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, Stifel Nicolaus increased their price objective on shares of Masimo from $165.00 to $170.00 and gave the company a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Masimo has a consensus rating of “Buy” and a consensus price target of $159.25.
Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.03. The business had revenue of $229.60 million during the quarter, compared to analysts’ expectations of $222.46 million. Masimo had a return on equity of 17.82% and a net margin of 22.15%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.73 earnings per share. On average, equities analysts predict that Masimo Co. will post 3.15 earnings per share for the current fiscal year.
In related news, CEO Joe E. Kiani sold 100,000 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $150.14, for a total value of $15,014,000.00. Following the sale, the chief executive officer now directly owns 239,241 shares in the company, valued at approximately $35,919,643.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joe E. Kiani sold 18,437 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $160.02, for a total transaction of $2,950,288.74. Following the completion of the sale, the chief executive officer now owns 157,678 shares in the company, valued at $25,231,633.56. The disclosure for this sale can be found here. Insiders sold 238,738 shares of company stock worth $36,108,247 in the last three months. Insiders own 11.50% of the company’s stock.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Read More: How is an ETF different from a mutual fund?
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.